IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome
Grant Award Details
Grant Type:
Grant Number:
CLIN1-11591
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$5,002,496
Status:
Closed
Progress Reports
Reporting Period:
Final Operational Milestone #6
Grant Application Details
Application Title:
IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome
Public Abstract:
Therapeutic Candidate or Device
CD4+ T cells that have undergone lentiviral -mediated gene transfer of Forkhead Box P3 (FOXP3) and acquired regulatory T cell function.
Indication
Immune dysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome
Therapeutic Mechanism
Administration of autologous CD4LVFOXP3 that constitutively and stably express wild-type FOXP3 gene will replace the lack of functional regulatory T cells in patients with IPEX syndrome, a life-threatening pediatric disease due to FOXP3 gene mutation, and a prototype of genetic autoimmune disease.
Unmet Medical Need
IPEX has early severe onset and is a serious clinical challenge. Pharmacological immunosuppression can only partially control autoimmune manifestations and does not prevent organ damage. Allogeneic HSCT can cure but lack of suitable donors and transplant complications lead to inferior outcomes.
Project Objective
Filing of IND application with the FDA
Major Proposed Activities
CD4+ T cells that have undergone lentiviral -mediated gene transfer of Forkhead Box P3 (FOXP3) and acquired regulatory T cell function.
Indication
Immune dysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome
Therapeutic Mechanism
Administration of autologous CD4LVFOXP3 that constitutively and stably express wild-type FOXP3 gene will replace the lack of functional regulatory T cells in patients with IPEX syndrome, a life-threatening pediatric disease due to FOXP3 gene mutation, and a prototype of genetic autoimmune disease.
Unmet Medical Need
IPEX has early severe onset and is a serious clinical challenge. Pharmacological immunosuppression can only partially control autoimmune manifestations and does not prevent organ damage. Allogeneic HSCT can cure but lack of suitable donors and transplant complications lead to inferior outcomes.
Project Objective
Filing of IND application with the FDA
Major Proposed Activities
- Complete nonclinical IND enabling safety and efficacy studies to meed the FDA requests.
- GMP FOXP3 lentiviral vector production to generate CD4LVFOXP3 cell product for clinical use and establish its GMP manufacturing process and scale up.
- File an Investigator New Drug (IND) application with the FDA to obtain approval to start the phase I clinical trial
Statement of Benefit to California:
IPEX syndrome not only impacts the affected patients but also directly impacts families and communities. Thus, improve treatment for IPEX patients would have tremendous personal benefit on the patients and their families and would provide a great economic benefit to the state. A successful outcome of this Treg replacement therapy in IPEX could support development of CD4LVFOXP3 cell product for other diseases with autoimmunity and immune dysregulation (e.g. IBD, T1D, scleroderma, acute GVHD).
Publications
- Clin Transl Immunology (2020): Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo. (PubMed: 33304583)